Carboplatin onkovis 10 mg/ml Infusionslösung
Sponsors
GWT-Tud GmbH, NSABP Foundation Inc.
Conditions
Adult patients with relapsed or primary refractory DLBCLPatients with early breast cancer
Phase 3
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"
CompletedCTIS2023-508472-11-00
Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
CompletedCTIS2023-508259-38-00
Start: 2021-04-29End: 2025-12-19Target: 302Updated: 2025-11-05